Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.

Dr. Coffey's visionary contributions to urological research in China and Japan.

Shimazaki J, Chung LW, Zhau HE, Ichikawa T.

Am J Clin Exp Urol. 2018 Apr 1;6(2):15-22. eCollection 2018. No abstract available.

2.

Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease Progression.

Ren S, Wei GH, Liu D, Wang L, Hou Y, Zhu S, Peng L, Zhang Q, Cheng Y, Su H, Zhou X, Zhang J, Li F, Zheng H, Zhao Z, Yin C, He Z, Gao X, Zhau HE, Chu CY, Wu JB, Collins C, Volik SV, Bell R, Huang J, Wu K, Xu D, Ye D, Yu Y, Zhu L, Qiao M, Lee HM, Yang Y, Zhu Y, Shi X, Chen R, Wang Y, Xu W, Cheng Y, Xu C, Gao X, Zhou T, Yang B, Hou J, Liu L, Zhang Z, Zhu Y, Qin C, Shao P, Pang J, Chung LWK, Xu J, Wu CL, Zhong W, Xu X, Li Y, Zhang X, Wang J, Yang H, Wang J, Huang H, Sun Y.

Eur Urol. 2017 Sep 18. pii: S0302-2838(17)30720-0. doi: 10.1016/j.eururo.2017.08.027. [Epub ahead of print]

PMID:
28927585
3.

Upregulation of minichromosome maintenance complex component 3 during epithelial-to-mesenchymal transition in human prostate cancer.

Stewart PA, Khamis ZI, Zhau HE, Duan P, Li Q, Chung LWK, Sang QA.

Oncotarget. 2017 Jun 13;8(24):39209-39217. doi: 10.18632/oncotarget.16835.

4.

MAOA-Dependent Activation of Shh-IL6-RANKL Signaling Network Promotes Prostate Cancer Metastasis by Engaging Tumor-Stromal Cell Interactions.

Wu JB, Yin L, Shi C, Li Q, Duan P, Huang JM, Liu C, Wang F, Lewis M, Wang Y, Lin TP, Pan CC, Posadas EM, Zhau HE, Chung LWK.

Cancer Cell. 2017 Mar 13;31(3):368-382. doi: 10.1016/j.ccell.2017.02.003.

5.

Bone Metastasis of Prostate Cancer Can Be Therapeutically Targeted at the TBX2-WNT Signaling Axis.

Nandana S, Tripathi M, Duan P, Chu CY, Mishra R, Liu C, Jin R, Yamashita H, Zayzafoon M, Bhowmick NA, Zhau HE, Matusik RJ, Chung LW.

Cancer Res. 2017 Mar 15;77(6):1331-1344. doi: 10.1158/0008-5472.CAN-16-0497. Epub 2017 Jan 20.

6.

Keratin 13 expression reprograms bone and brain metastases of human prostate cancer cells.

Li Q, Yin L, Jones LW, Chu GC, Wu JB, Huang JM, Li Q, You S, Kim J, Lu YT, Mrdenovic S, Wang R, Freeman MR, Garraway I, Lewis MS, Chung LW, Zhau HE.

Oncotarget. 2016 Dec 20;7(51):84645-84657. doi: 10.18632/oncotarget.13175.

7.

Cultured circulating tumor cells and their derived xenografts for personalized oncology.

Wang R, Chu GCY, Mrdenovic S, Annamalai AA, Hendifar AE, Nissen NN, Tomlinson JS, Lewis M, Palanisamy N, Tseng HR, Posadas EM, Freeman MR, Pandol SJ, Zhau HE, Chung LWK.

Asian J Urol. 2016 Oct;3(4):240-253. doi: 10.1016/j.ajur.2016.08.005. Epub 2016 Aug 25. Review.

8.

Combined cell surface carbonic anhydrase 9 and CD147 antigens enable high-efficiency capture of circulating tumor cells in clear cell renal cell carcinoma patients.

Liu S, Tian Z, Zhang L, Hou S, Hu S, Wu J, Jing Y, Sun H, Yu F, Zhao L, Wang R, Tseng HR, Zhau HE, Chung LW, Wu K, Wang H, Wu JB, Nie Y, Shao C.

Oncotarget. 2016 Sep 13;7(37):59877-59891. doi: 10.18632/oncotarget.10979.

9.

SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer.

Gururajan M, Cavassani KA, Sievert M, Duan P, Lichterman J, Huang JM, Smith B, You S, Nandana S, Chu GC, Mink S, Josson S, Liu C, Morello M, Jones LW, Kim J, Freeman MR, Bhowmick N, Zhau HE, Chung LW, Posadas EM.

Oncotarget. 2015 Dec 29;6(42):44072-83. doi: 10.18632/oncotarget.6398.

10.

Near-infrared fluorescence heptamethine carbocyanine dyes mediate imaging and targeted drug delivery for human brain tumor.

Wu JB, Shi C, Chu GC, Xu Q, Zhang Y, Li Q, Yu JS, Zhau HE, Chung LW.

Biomaterials. 2015 Oct;67:1-10. doi: 10.1016/j.biomaterials.2015.07.028. Epub 2015 Jul 16.

11.

Metastasis initiating cells in primary prostate cancer tissues from transurethral resection of the prostate (TURP) predicts castration-resistant progression and survival of prostate cancer patients.

Li Q, Li Q, Nuccio J, Liu C, Duan P, Wang R, Jones LW, Chung LW, Zhau HE.

Prostate. 2015 Sep;75(12):1312-21. doi: 10.1002/pros.23011. Epub 2015 May 19.

12.

Subclassification of prostate cancer circulating tumor cells by nuclear size reveals very small nuclear circulating tumor cells in patients with visceral metastases.

Chen JF, Ho H, Lichterman J, Lu YT, Zhang Y, Garcia MA, Chen SF, Liang AJ, Hodara E, Zhau HE, Hou S, Ahmed RS, Luthringer DJ, Huang J, Li KC, Chung LW, Ke Z, Tseng HR, Posadas EM.

Cancer. 2015 Sep 15;121(18):3240-51. doi: 10.1002/cncr.29455. Epub 2015 May 14.

13.

Monoamine oxidase A inhibitor-near-infrared dye conjugate reduces prostate tumor growth.

Wu JB, Lin TP, Gallagher JD, Kushal S, Chung LW, Zhau HE, Olenyuk BZ, Shih JC.

J Am Chem Soc. 2015 Feb 18;137(6):2366-74. doi: 10.1021/ja512613j. Epub 2015 Jan 27.

PMID:
25585152
14.

Heptamethine carbocyanine dye-mediated near-infrared imaging of canine and human cancers through the HIF-1α/OATPs signaling axis.

Shi C, Wu JB, Chu GC, Li Q, Wang R, Zhang C, Zhang Y, Kim HL, Wang J, Zhau HE, Pan D, Chung LW.

Oncotarget. 2014 Oct 30;5(20):10114-26.

15.

miR-154* and miR-379 in the DLK1-DIO3 microRNA mega-cluster regulate epithelial to mesenchymal transition and bone metastasis of prostate cancer.

Gururajan M, Josson S, Chu GC, Lu CL, Lu YT, Haga CL, Zhau HE, Liu C, Lichterman J, Duan P, Posadas EM, Chung LW.

Clin Cancer Res. 2014 Dec 15;20(24):6559-69. doi: 10.1158/1078-0432.CCR-14-1784. Epub 2014 Oct 16.

16.

Stromal fibroblast-derived miR-409 promotes epithelial-to-mesenchymal transition and prostate tumorigenesis.

Josson S, Gururajan M, Sung SY, Hu P, Shao C, Zhau HE, Liu C, Lichterman J, Duan P, Li Q, Rogatko A, Posadas EM, Haga CL, Chung LW.

Oncogene. 2015 May 21;34(21):2690-9. doi: 10.1038/onc.2014.212. Epub 2014 Jul 28.

PMID:
25065597
17.

miR-409-3p/-5p promotes tumorigenesis, epithelial-to-mesenchymal transition, and bone metastasis of human prostate cancer.

Josson S, Gururajan M, Hu P, Shao C, Chu GY, Zhau HE, Liu C, Lao K, Lu CL, Lu YT, Lichterman J, Nandana S, Li Q, Rogatko A, Berel D, Posadas EM, Fazli L, Sareen D, Chung LW.

Clin Cancer Res. 2014 Sep 1;20(17):4636-46. doi: 10.1158/1078-0432.CCR-14-0305. Epub 2014 Jun 24.

18.

Near-infrared fluorescence imaging of cancer mediated by tumor hypoxia and HIF1α/OATPs signaling axis.

Wu JB, Shao C, Li X, Shi C, Li Q, Hu P, Chen YT, Dou X, Sahu D, Li W, Harada H, Zhang Y, Wang R, Zhau HE, Chung LW.

Biomaterials. 2014 Sep;35(28):8175-85. doi: 10.1016/j.biomaterials.2014.05.073. Epub 2014 Jun 21.

19.

Monoamine oxidase A mediates prostate tumorigenesis and cancer metastasis.

Wu JB, Shao C, Li X, Li Q, Hu P, Shi C, Li Y, Chen YT, Yin F, Liao CP, Stiles BL, Zhau HE, Shih JC, Chung LW.

J Clin Invest. 2014 Jul;124(7):2891-908. doi: 10.1172/JCI70982. Epub 2014 May 27.

20.

Detection of live circulating tumor cells by a class of near-infrared heptamethine carbocyanine dyes in patients with localized and metastatic prostate cancer.

Shao C, Liao CP, Hu P, Chu CY, Zhang L, Bui MH, Ng CS, Josephson DY, Knudsen B, Tighiouart M, Kim HL, Zhau HE, Chung LW, Wang R, Posadas EM.

PLoS One. 2014 Feb 14;9(2):e88967. doi: 10.1371/journal.pone.0088967. eCollection 2014.

21.

RANK- and c-Met-mediated signal network promotes prostate cancer metastatic colonization.

Chu GC, Zhau HE, Wang R, Rogatko A, Feng X, Zayzafoon M, Liu Y, Farach-Carson MC, You S, Kim J, Freeman MR, Chung LW.

Endocr Relat Cancer. 2014 Mar 4;21(2):311-26. doi: 10.1530/ERC-13-0548. Print 2014 Apr.

22.

Convergent RANK- and c-Met-mediated signaling components predict survival of patients with prostate cancer: an interracial comparative study.

Hu P, Chung LW, Berel D, Frierson HF, Yang H, Liu C, Wang R, Li Q, Rogatko A, Zhau HE.

PLoS One. 2013 Sep 16;8(9):e73081. doi: 10.1371/journal.pone.0073081. eCollection 2013.

23.

Interracial differences in prostate cancer progression among patients from the United States, China and Japan.

Zhau HE, Li Q, Chung LW.

Asian J Androl. 2013 Nov;15(6):705-7. doi: 10.1038/aja.2013.86. Epub 2013 Jul 22.

24.

β2-Microglobulin-mediated signaling as a target for cancer therapy.

Nomura T, Huang WC, Zhau HE, Josson S, Mimata H, Chung LW.

Anticancer Agents Med Chem. 2014 Mar;14(3):343-52. Review.

25.

Epidermal growth factor promotes protein degradation of epithelial protein lost in neoplasm (EPLIN), a putative metastasis suppressor, during epithelial-mesenchymal transition.

Zhang S, Wang X, Iqbal S, Wang Y, Osunkoya AO, Chen Z, Chen Z, Shin DM, Yuan H, Wang YA, Zhau HE, Chung LW, Ritenour C, Kucuk O, Wu D.

J Biol Chem. 2013 Jan 18;288(3):1469-79. doi: 10.1074/jbc.M112.438341. Epub 2012 Nov 27.

26.

Optical imaging of kidney cancer with novel near infrared heptamethine carbocyanine fluorescent dyes.

Yang X, Shao C, Wang R, Chu CY, Hu P, Master V, Osunkoya AO, Kim HL, Zhau HE, Chung LWK.

J Urol. 2013 Feb;189(2):702-710. doi: 10.1016/j.juro.2012.09.056. Epub 2012 Sep 20.

27.

Spontaneous cancer-stromal cell fusion as a mechanism of prostate cancer androgen-independent progression.

Wang R, Sun X, Wang CY, Hu P, Chu CY, Liu S, Zhau HE, Chung LW.

PLoS One. 2012;7(8):e42653. doi: 10.1371/journal.pone.0042653. Epub 2012 Aug 3.

28.

PDGF upregulates Mcl-1 through activation of β-catenin and HIF-1α-dependent signaling in human prostate cancer cells.

Iqbal S, Zhang S, Driss A, Liu ZR, Kim HR, Wang Y, Ritenour C, Zhau HE, Kucuk O, Chung LW, Wu D.

PLoS One. 2012;7(1):e30764. doi: 10.1371/journal.pone.0030764. Epub 2012 Jan 20.

29.

Differentiation of human mesenchymal stem cell spheroids under microgravity conditions.

Cerwinka WH, Sharp SM, Boyan BD, Zhau HE, Chung LW, Yates C.

Cell Regen (Lond). 2012 Jun 28;1(1):2. doi: 10.1186/2045-9769-1-2. eCollection 2012.

30.

Multiplexed quantum dot labeling of activated c-Met signaling in castration-resistant human prostate cancer.

Hu P, Chu GC, Zhu G, Yang H, Luthringer D, Prins G, Habib F, Wang Y, Wang R, Chung LW, Zhau HE.

PLoS One. 2011;6(12):e28670. doi: 10.1371/journal.pone.0028670. Epub 2011 Dec 21.

31.

LIV-1 promotes prostate cancer epithelial-to-mesenchymal transition and metastasis through HB-EGF shedding and EGFR-mediated ERK signaling.

Lue HW, Yang X, Wang R, Qian W, Xu RZ, Lyles R, Osunkoya AO, Zhou BP, Vessella RL, Zayzafoon M, Liu ZR, Zhau HE, Chung LW.

PLoS One. 2011;6(11):e27720. doi: 10.1371/journal.pone.0027720. Epub 2011 Nov 16.

32.

Serum prosaposin levels are increased in patients with advanced prostate cancer.

Koochekpour S, Hu S, Vellasco-Gonzalez C, Bernardo R, Azabdaftari G, Zhu G, Zhau HE, Chung LW, Vessella RL.

Prostate. 2012 Feb;72(3):253-69. doi: 10.1002/pros.21427. Epub 2011 May 31. Erratum in: Prostate. 2014 May;74(7):804.

33.

EPLIN downregulation promotes epithelial-mesenchymal transition in prostate cancer cells and correlates with clinical lymph node metastasis.

Zhang S, Wang X, Osunkoya AO, Iqbal S, Wang Y, Chen Z, Müller S, Chen Z, Josson S, Coleman IM, Nelson PS, Wang YA, Wang R, Shin DM, Marshall FF, Kucuk O, Chung LW, Zhau HE, Wu D.

Oncogene. 2011 Dec 15;30(50):4941-52. doi: 10.1038/onc.2011.199. Epub 2011 May 30.

34.

Active sonic hedgehog signaling between androgen independent human prostate cancer cells and normal/benign but not cancer-associated prostate stromal cells.

Shigemura K, Huang WC, Li X, Zhau HE, Zhu G, Gotoh A, Fujisawa M, Xie J, Marshall FF, Chung LW.

Prostate. 2011 Dec;71(16):1711-22. doi: 10.1002/pros.21388. Epub 2011 Apr 25.

35.

Immunohistochemical characterization of sonic hedgehog and its downstream signaling molecules during human penile development.

Shehata BM, Elmore JM, Bootwala Y, Steelman CK, Bare JB, Shoffeitt CJ, Wang R, Zhau HE, He D, Zhu G, Chung LW.

Fetal Pediatr Pathol. 2011;30(4):244-51. doi: 10.3109/15513815.2011.555809. Epub 2011 Mar 24.

PMID:
21434830
36.

β2-microglobulin induces epithelial to mesenchymal transition and confers cancer lethality and bone metastasis in human cancer cells.

Josson S, Nomura T, Lin JT, Huang WC, Wu D, Zhau HE, Zayzafoon M, Weizmann MN, Gururajan M, Chung LW.

Cancer Res. 2011 Apr 1;71(7):2600-10. doi: 10.1158/0008-5472.CAN-10-3382. Epub 2011 Mar 22.

37.

PrLZ protects prostate cancer cells from apoptosis induced by androgen deprivation via the activation of Stat3/Bcl-2 pathway.

Zhang D, He D, Xue Y, Wang R, Wu K, Xie H, Zeng J, Wang X, Zhau HE, Chung LW, Chang LS, Li L.

Cancer Res. 2011 Mar 15;71(6):2193-202. doi: 10.1158/0008-5472.CAN-10-1791. Epub 2011 Mar 8.

38.

Human prostate cancer harbors the stem cell properties of bone marrow mesenchymal stem cells.

Zhau HE, He H, Wang CY, Zayzafoon M, Morrissey C, Vessella RL, Marshall FF, Chung LW, Wang R.

Clin Cancer Res. 2011 Apr 15;17(8):2159-69. doi: 10.1158/1078-0432.CCR-10-2523. Epub 2011 Feb 25.

39.

Near IR heptamethine cyanine dye-mediated cancer imaging.

Yang X, Shi C, Tong R, Qian W, Zhau HE, Wang R, Zhu G, Cheng J, Yang VW, Cheng T, Henary M, Strekowski L, Chung LW.

Clin Cancer Res. 2010 May 15;16(10):2833-44. doi: 10.1158/1078-0432.CCR-10-0059. Epub 2010 Apr 21.

40.

Matched pairs of human prostate stromal cells display differential tropic effects on LNCaP prostate cancer cells.

Sun X, He H, Xie Z, Qian W, Zhau HE, Chung LW, Marshall FF, Wang R.

In Vitro Cell Dev Biol Anim. 2010 Jun;46(6):538-46. doi: 10.1007/s11626-010-9309-z. Epub 2010 Apr 10.

41.

Phorbol ester phorbol-12-myristate-13-acetate induces epithelial to mesenchymal transition in human prostate cancer ARCaPE cells.

He H, Davidson AJ, Wu D, Marshall FF, Chung LW, Zhau HE, He D, Wang R.

Prostate. 2010 Jul 1;70(10):1119-26. doi: 10.1002/pros.21146.

42.

Differential expression of the alpha2 chain of the interleukin-13 receptor in metastatic human prostate cancer ARCaPM cells.

He H, Xu J, Nelson PS, Marshall FF, Chung LW, Zhau HE, He D, Wang R.

Prostate. 2010 Jun 15;70(9):993-1001. doi: 10.1002/pros.21133.

43.

Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells.

Zhang S, Zhau HE, Osunkoya AO, Iqbal S, Yang X, Fan S, Chen Z, Wang R, Marshall FF, Chung LW, Wu D.

Mol Cancer. 2010 Jan 19;9:9. doi: 10.1186/1476-4598-9-9.

44.

Androgen receptor survival signaling is blocked by anti-beta2-microglobulin monoclonal antibody via a MAPK/lipogenic pathway in human prostate cancer cells.

Huang WC, Zhau HE, Chung LW.

J Biol Chem. 2010 Mar 12;285(11):7947-56. doi: 10.1074/jbc.M109.092759. Epub 2010 Jan 13.

45.

Tumor-stroma co-evolution in prostate cancer progression and metastasis.

Josson S, Matsuoka Y, Chung LW, Zhau HE, Wang R.

Semin Cell Dev Biol. 2010 Feb;21(1):26-32. doi: 10.1016/j.semcdb.2009.11.016. Epub 2009 Dec 3. Review.

46.

Progressive epithelial to mesenchymal transitions in ARCaP E prostate cancer cells during xenograft tumor formation and metastasis.

He H, Yang X, Davidson AJ, Wu D, Marshall FF, Chung LW, Zhau HE, Wang R.

Prostate. 2010 Apr 1;70(5):518-28. doi: 10.1002/pros.21086.

47.

Human prostate fibroblasts induce growth and confer castration resistance and metastatic potential in LNCaP Cells.

Thalmann GN, Rhee H, Sikes RA, Pathak S, Multani A, Zhau HE, Marshall FF, Chung LW.

Eur Urol. 2010 Jul;58(1):162-71. doi: 10.1016/j.eururo.2009.08.026. Epub 2009 Sep 4.

48.

Visualizing human prostate cancer cells in mouse skeleton using bioconjugated near-infrared fluorescent quantum dots.

Shi C, Zhu Y, Xie Z, Qian W, Hsieh CL, Nie S, Su Y, Zhau HE, Chung LW.

Urology. 2009 Aug;74(2):446-51. doi: 10.1016/j.urology.2009.01.023. Epub 2009 May 9.

49.

Soluble factors derived from stroma activated androgen receptor phosphorylation in human prostate LNCaP cells: roles of ERK/MAP kinase.

Shigemura K, Isotani S, Wang R, Fujisawa M, Gotoh A, Marshall FF, Zhau HE, Chung LW.

Prostate. 2009 Jun 15;69(9):949-55. doi: 10.1002/pros.20944.

50.

Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis.

Sung SY, Hsieh CL, Law A, Zhau HE, Pathak S, Multani AS, Lim S, Coleman IM, Wu LC, Figg WD, Dahut WL, Nelson P, Lee JK, Amin MB, Lyles R, Johnstone PA, Marshall FF, Chung LW.

Cancer Res. 2008 Dec 1;68(23):9996-10003. doi: 10.1158/0008-5472.CAN-08-2492.

Supplemental Content

Support Center